The Global Cardiac Rhythm Management Devices Market, by Product Type (Cardiac Resynchronization Therapy Devices, Defibrillator, and Pacemakers), by End User (Hospitals, Home Care Settings, and Ambulatory Care Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 19.05 billion in 2017, and is projected to exhibit a CAGR of 7.5% over the forecast period (2018 - 2026),.
Cardiac Rhythm Management (CRM) devices perform many functions, including monitoring for arrhythmias, bradycardia pacing, cardiac resynchronisation for heart failure, defibrillation and anti-tachycardia pacing for tachyarrhythmias. In the past few decades, use of cardiac rhythm management devices has increased worldwide due to increase in life expectancy and technological developments in products such as cardiac resynchronization therapy (CRT). Increasing consumption of caffeine is the most common factor linked with abnormal heart rhythms. Furthermore, excessive consumption of red wine can lead to symptoms of arrhythmias. Substances such as automobile emissions, cigarette smoke, pollution from industrial plants, paint thinners, and propane gas can also result into problems related to cardiac rhythms. However, high product price and infection risks associated with product implantation are the major concerns for manufacturers, as these are obstructing the product adoption. As per the study published by the National Cardiovascular Data Registry 2014, implantable cardioverter defibrillator infection rate has been reported to be around 1.7%. It is the third leading cause of complications occur due to CRM devices.
According to a study published in Health Affairs, the average price for a dual-chamber pacemaker in Germany was US$ 1,400 in 2014 and in the U.S. it was US$ 4,200. Moreover, risks associated with product design is major concern for developers. In November 2018, Boston Scientific issued a hazard alert in Australia regarding its SQ-RX Model 1010 Pulse Generator in some of the first-generation subcutaneous implantable cardioverter defibrillator (S-ICD) systems. Future innovations in CRM products is expected to shift from transvenous leads to leadless designs with combinations of different components on a modular basis according to the function required. Moreover, CRM devices with remote controlling such as implantable cardioverter defibrillators and pacemakers can send information from the device to a portable unit, which allows the healthcare professional to monitor the patient condition at any time.
Browse 28 Market Data Tables and 24 Figures spread through 155 Pages and in-depth TOC on "Cardiac Rhythm Management Devices Market, by Product Type (Cardiac Resynchronization Therapy Devices, Defibrillator, and Pacemakers), by End User (Hospitals, Home Care Settings, and Ambulatory Care Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to cardiac rhythm management devices market, click the link below:
https://www.coherentmarketinsights.com/market-insight/cardiac-rhythm-management-devices-market-2364
Key Takeaways of the Cardiac Rhythm Management Devices Market:
- The global cardiac rhythm management devices market is expected to expand at a CAGR of 7.5% during the forecast period (2018–2026), owing to increasing number of arrhythmias patients globally. According to the Center for Diseases Control and Prevention (CDC) 2017 data, an estimated 2.7 to 6.1 million people in the U.S. have heart arrhythmias.
- Among region, Asia Pacific is expected to generate significant revenue in 2018, due to rising adoption of cardiac rhythm management devices in the region. According to the Heart, Lung and Circulation Journal 2015 study, around 20,000 cardiac rhythm management devices are implanted across Australia annually, around three-quarters of which are pacemakers.
- Major players operating in the global cardiac rhythm management devices market include Medtronic plc., Abbott Laboratories, Abiomed, Boston Scientific Corporation, Biotronik Se Co Kg, Koninklijke Philips N.V., LivaNova Plc., Cardiac Science Corporation, Schiller Ag, and Zoll Medical Corporation
